• 1. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 2. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 3. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 4. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 5. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Very long-chain fatty acids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates Very long-chain fatty acids

Introduction to (5Z,7S,8E,10Z,13Z,15E,17S,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoic Acid (CAS No. 578008-43-2)

The compound (5Z,7S,8E,10Z,13Z,15E,17S,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoic acid, identified by the CAS number 578008-43-2, is a highly specialized polyunsaturated fatty acid (PUFA) with a unique structural configuration. This compound has garnered significant attention in the field of chemobiology due to its potential therapeutic applications and its role in modulating various biological pathways. The intricate arrangement of double bonds and hydroxyl groups in its molecular structure contributes to its distinct chemical properties and biological activities.

Polyunsaturated fatty acids are well-known for their importance in human health and their involvement in a multitude of physiological processes. Among these PUFAs, docosahexaenoic acid (DHA) is particularly notable for its role in brain development and function. The compound in question shares a similar backbone but with additional hydroxyl groups and a different configuration of double bonds. This structural variation imparts unique characteristics that make it a subject of intense research interest.

Recent studies have highlighted the potential of this compound as an anti-inflammatory agent. Inflammation is a key pathological process underlying numerous chronic diseases, including cardiovascular disorders, arthritis, and neurodegenerative conditions. The ability of (5Z,7S,8E,10Z,13Z,15E,17S,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoic acid to modulate inflammatory pathways has been demonstrated through both in vitro and in vivo experiments. These studies suggest that the compound can inhibit the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), thereby reducing inflammation.

Additionally，the compound has shown promise in the context of cardiovascular health. Research indicates that it can help improve endothelial function by enhancing the production of nitric oxide (NO), a molecule crucial for vasodilation and blood pressure regulation. Moreover，it has been observed to reduce LDL cholesterol levels and prevent the oxidation of LDL cholesterol，both of which are critical factors in the development of atherosclerosis.

Another area where this compound has drawn attention is neuroprotection. Studies have suggested that it may have neuroprotective effects by reducing oxidative stress and inflammation in neural cells. This is particularly relevant given the increasing prevalence of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. The ability of (5Z，7S，8E，10Z，13Z，15E，17S，19Z)-7，17-dihydroxydocosa-5，8，10，13，15，19-hexaenoic acid to cross the blood-brain barrier further enhances its potential as a therapeutic agent for neurological disorders.

The synthesis of this compound presents a significant challenge due to its complex stereochemistry. Traditional synthetic methods often require multiple steps and careful control of reaction conditions to achieve high enantiomeric purity. However， advances in synthetic chemistry have made it possible to produce this compound with greater efficiency and precision. These advancements not only facilitate research but also open up possibilities for large-scale production for therapeutic purposes.

In terms of clinical applications，the compound is currently being evaluated in several preclinical studies aimed at assessing its safety and efficacy in treating various diseases. The results from these studies are expected to provide valuable insights into its potential as a therapeutic agent. If successful，this compound could represent a significant advancement in the treatment of inflammatory、cardiovascular、and neurodegenerative diseases.

The growing interest in this compound also reflects broader trends in the pharmaceutical industry towards developing targeted therapies based on natural products or derivatives thereof。The unique chemical structure of (5Z，7S，8E，10Z，13Z，15E，17S?19Z)-7?17-dihydroxydocosa-5、8、10、13、15、19-hexaenoic acid makes it an attractive candidate for further exploration as a lead compound or an adjunct therapy in combination with existing treatments.

Future research directions may include exploring synthetic modifications to enhance the bioavailability or stability of the compound。Additionally，，investigators may investigate its mechanisms of action at a more molecular level to identify new therapeutic targets。The integration of computational modeling with experimental techniques could also provide deeper insights into how this compound interacts with biological systems.

In conclusion?(5Z，7S，8E?10Z?13Z?15E?17S、19Z)-7、17-dihydroxydocosa-5、8、10、13、15、19-hexaenoic acid (CAS No.578008-43-2) is a promising compound with significant potential in the field of chemobiology。Its unique structure and demonstrated biological activities make it a valuable subject for further research aimed at developing new treatments for various diseases。As our understanding of its properties continues to grow，，so too will its potential applications in medicine。

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)